30 pharmaceutical sales associate jobs found

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

To be eligible for this position, you must reside in the same country where the job is located. Associate Business Development Director – Safety & Regulatory Solutions Location: US – Greater Boston area, NY/NJ, VA/DC Metro, CA areas The Associate Business Development Director works collaboratively with other colleagues to increase sales of IQVIA’s Safety and Regulatory services and technology within the life sciences industry. Responsibilities include full cycle sales including: target identification, securing and managing client meetings, listening and understanding client needs, addressing client concerns/objections, managing Subject Matter Experts in defining opportunities, proposing solutions, negotiating, obtaining SOWs and closing the deal. Our Sales Professionals are expected to quickly develop credibility with customers/prospects and build trust through professionalism and knowledge of services and products. Essential Duties and Responsibilities:...

Regeneron is seeking an Associate Director, Sales Forecasting & Analytics to act as a leading business partner to the Commercial functions responsible for supporting financial and operational decisions that may impact product and business unit revenue. In this role you will be responsible for the generation, analysis, tracking and dissemination of the commercial revenue forecasts, analyzing actual sales performance and providing related insights for Regeneron’s marketed and new Oncology products. A Typical Day In The Role Might Look Like: Develop and maintain patient-based forecast model applying a mix of epidemiology, secondary data, and primary market research-based sources resulting in detailed patient flow buildout and all relevant variables to produce and analyze revenue forecasts. Convert assumptions to demand sales units, gross and net sales. Understand and analyze actuals, perform revenue variance analysis to isolate and articulate performance drivers. Work...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Job Description The Position The District Business Manager (DBM), Dermatology will report to the Regional Director, Dermatology and be responsible for hiring, leading, developing and retaining Dermatology Sales Representatives in their assigned district. The DM will work inter-departmentally to ensure strong and consistent sales performance that exceeds forecast and expectations relating to product goals and drive accountability for all results throughout the district. DBM's will work to accomplish all goals in an ethical manner with a high degree of integrity strictly following all our company's compliance policies and procedures governing the promotion of pharmaceutical products in the US. Responsibilities  Develop, implement, and measure outcomes of strategic business plans in order to meet sales objectives while in accordance with all applicable company and regulatory standards. Meet or exceed sales goals and objectives for designated products and/or...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

"This role is field-based, and the territory will cover the southeast region. Candidates should live within a reasonable distance from the primary city." Direct the sales strategy and planning for field based team by driving agreed upon short term sales targets and long-term goals and objectives. Continue to position AbbVie as a market leader and solution-provider across the stakeholder base. Responsibilities Exhibit intense deep and broad market knowledge across the sector, geography and franchise(s), including Key Managed Care and Payer dynamics. Share and provide quantitative and qualitative business acumen and analysis. Drive and position AbbVie in high growth. Determine franchise logical strategic next steps and deliver financial results in both top- and relevant bottom-lines. Ensure all facets of the external market, segment and internal enterprise are considered in the strategy and plan setting. Provide compelling coaching, mentoring and guidance across the...

"This role is field-based, and the territory will cover the southeast region. Candidates should live within a reasonable distance from the primary city." Direct the sales strategy and planning for field based team by driving agreed upon short term sales targets and long-term goals and objectives. Continue to position AbbVie as a market leader and solution-provider across the stakeholder base. Responsibilities Exhibit intense deep and broad market knowledge across the sector, geography and franchise(s), including Key Managed Care and Payer dynamics. Share and provide quantitative and qualitative business acumen and analysis. Drive and position AbbVie in high growth. Determine franchise logical strategic next steps and deliver financial results in both top- and relevant bottom-lines. Ensure all facets of the external market, segment and internal enterprise are considered in the strategy and plan setting. Provide compelling coaching, mentoring and guidance across the...

"This role is field-based, and the territory will cover the southeast region. Candidates should live within a reasonable distance from the primary city." Direct the sales strategy and planning for field based team by driving agreed upon short term sales targets and long-term goals and objectives. Continue to position AbbVie as a market leader and solution-provider across the stakeholder base. Responsibilities Exhibit intense deep and broad market knowledge across the sector, geography and franchise(s), including Key Managed Care and Payer dynamics. Share and provide quantitative and qualitative business acumen and analysis. Drive and position AbbVie in high growth. Determine franchise logical strategic next steps and deliver financial results in both top- and relevant bottom-lines. Ensure all facets of the external market, segment and internal enterprise are considered in the strategy and plan setting. Provide compelling coaching, mentoring and guidance across the...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at  www.axsome.com  and follow us on  LinkedIn  and  X . About This Role   Axsome Therapeutics...

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at  www.axsome.com  and follow us on  LinkedIn  and  X . About This Role   Axsome Therapeutics...

The primary objective of this position is to lead the end-to-end Demand and Revenue forecasting process for the US Immunology Business Unit, overall RINVOQ, SKYRIZI, and HUMIRA brand forecast consolidation. The position is responsible for driving the development, maintenance, harmonization, and continuous improvement of the various forecasting models used to produce commercial revenue projections for all Planning Cycles (LBE, Plan, LRP) and launch assessments as well as all associated analytics and supporting presentation materials for review with all levels of brand and AbbVie leadership. The individual must develop and maintain a strong knowledge of the business to facilitate optimal decision making through cross functional collaboration with Sales & Marketing Management, Marketing Analytics, Market Access, Commercial Finance, Operations, and external collaboration partners.  This position will report to the Finance Director, US Immunology Consolidations & Governance COE,...

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at  www.axsome.com  and follow us on  LinkedIn  and  X . About This Role   Axsome Therapeutics...

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at  www.axsome.com  and follow us on  LinkedIn  and  X . About This Role   Axsome Therapeutics...